// App-Quantinova.ai

1536 : T-cell inflamed phenotype gene expression signatures to predict clinical benefit from pembrolizumab across multiple tumor types.

Researchers

Presenter

  • Sarina Anne Piha-Paul

Principal Investigators

  • Jaafar Bennouna

  • Andrew Albright

  • Michael Nebozhyn

  • Terrill McClanahan

  • Mark Ayers

  • Jared K. Lunceford

  • Patrick Alexander Ott

Medical Centers

  • Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX

  • Institut de Cancerologie de l'Ouestsite Rene Gauducheau, Saint Herblain, France

  • Merck & Co., Inc., Kenilworth, NJ

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • United States

  • France

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02054806

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved